Vermillion Announces Notice of Issuance of U.S. Patent Covering Hepcidin as a Biomarker for Ovarian Cancer
News Apr 06, 2009
Vermillion, Inc. has announced that the U.S. Patent Office (USPTO) has issued a notice of allowance to the Company for the discovery of hepcidin as a biomarker for ovarian cancer.
The discovery could ultimately lead to the development of an improved, next-generation assay that might provide physicians with additional, valuable information to diagnose ovarian cancer.
"The notice of issuance of this patent validates the strength of our approach in the development of innovative molecular diagnostics," said Eric T. Fung, M.D., Ph.D, Chief Scientific Officer of Vermillion and co-inventor. "This patent comprises an important component of our ovarian cancer patent portfolio."
The patent also covers the measurement of hepcidin by a variety of methods, including mass spectrometry and other immunoassay approaches.
CRISPR Reveals the Sugary Secrets of the Cancer-related Notch ProteinNews
New research shows that the fucose and glucose modifications serve as quality-control markers that allow Notch to be transported to its final destination in the cell membrane.READ MORE
Sugar Molecule Helps Stomach Cells to Differentiate Between Good and Bad BugsNews
Max Planck scientists discover novel innate surveillance mechanism to fight off pathogenic Helicobacter strains.READ MORE
Air Quality in “Green” Housing Affected by Toxic Chemicals in Building MaterialsNews
Researchers tested for nearly 100 chemicals—including phthalates, flame retardants, pesticides, antimicrobials, fragrances, formaldehyde, and chlorinated solvents. Findings could lead to healthier homes, especially for low-income groups living in subsidized housing.READ MORE